Eisai's top US executive earned more than CEO
This article was originally published in Scrip
Eisai's top executive in the US was paid more than the company's CEO last fiscal year, according to information provided by the Japanese firm under new disclosure rules.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.